Legal & General Group
RGNX icon

Legal & General Group’s Regenxbio RGNX Stock Holding History

Legal & General Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.7K Hold
4,022
– – ﹤0.01% 2786
2025
Q4 		$57.9K Sell
4,022
-288
-7% -$3.59K ﹤0.01% 2702
2025
Q3 		$41.6K Hold
4,310
– – ﹤0.01% 2773
2025
Q2 		$35.4K Sell
4,310
-4,480
-51% -$37.5K ﹤0.01% 2790
2025
Q1 		$62.8K Sell
8,790
-36,033
-80% -$268K ﹤0.01% 2710
2024
Q4 		$346K Sell
44,823
-72,905
-62% -$685K ﹤0.01% 2576
2024
Q3 		$1.23M Buy
117,728
+148
+0.1% +$1.8K ﹤0.01% 2160
2024
Q2 		$1.38M Buy
117,580
+5,740
+5% +$89.3K ﹤0.01% 2093
2024
Q1 		$2.36M Buy
111,840
+1,662
+2% +$29.6K ﹤0.01% 1872
2023
Q4 		$1.98M Buy
110,178
+124
+0.1% +$2.18K ﹤0.01% 1963
2023
Q3 		$1.81M Buy
110,054
+1,325
+1% +$24K ﹤0.01% 1942
2023
Q2 		$2.17M Sell
108,729
-3,268
-3% -$63K ﹤0.01% 1890
2023
Q1 		$2.12M Sell
111,997
-1,126
-1% -$24.9K ﹤0.01% 1858
2022
Q4 		$2.57M Buy
113,123
+2,720
+2% +$61.5K ﹤0.01% 1758
2022
Q3 		$2.92M Buy
110,403
+2,046
+2% +$60.7K ﹤0.01% 1660
2022
Q2 		$2.68M Sell
108,357
-147
-0.1% -$3.67K ﹤0.01% 1731
2022
Q1 		$3.6M Sell
108,504
-450
-0.4% -$12.5K ﹤0.01% 1702
2021
Q4 		$3.56M Buy
108,954
+3,530
+3% +$120K ﹤0.01% 1754
2021
Q3 		$4.42M Buy
105,424
+11,449
+12% +$412K ﹤0.01% 1617
2021
Q2 		$3.65M Sell
93,975
-22,618
-19% -$809K ﹤0.01% 1703
2021
Q1 		$3.98M Buy
116,593
+17,481
+18% +$746K ﹤0.01% 1683
2020
Q4 		$4.5M Buy
99,112
+392
+0.4% +$13.7K ﹤0.01% 1512
2020
Q3 		$2.72M Sell
98,720
-4,701
-5% -$153K ﹤0.01% 1634
2020
Q2 		$3.81M Buy
103,421
+7,201
+7% +$268K ﹤0.01% 1431
2020
Q1 		$3.12M Buy
96,220
+633
+0.7% +$26.4K ﹤0.01% 1387
2019
Q4 		$3.92M Buy
95,587
+10,238
+12% +$404K ﹤0.01% 1494
2019
Q3 		$3.04M Buy
85,349
+3,830
+5% +$155K ﹤0.01% 1534
2019
Q2 		$4.19M Buy
81,519
+434
+0.5% +$21.7K ﹤0.01% 1363
2019
Q1 		$4.65M Buy
81,085
+7,663
+10% +$380K ﹤0.01% 1222
2018
Q4 		$3.07M Buy
73,422
+3,514
+5% +$206K ﹤0.01% 1350
2018
Q3 		$5.28M Buy
69,908
+16,522
+31% +$1.19M ﹤0.01% 1130
2018
Q2 		$3.83M Buy
53,386
+48,150
+920% +$2.3M ﹤0.01% 1291
2018
Q1 		$156K Sell
5,236
-1,630
-24% -$47.4K ﹤0.01% 2360
2017
Q4 		$229K Sell
6,866
-354
-5% -$10.7K ﹤0.01% 2271
2017
Q3 		$238K Buy
7,220
+350
+5% +$7.88K ﹤0.01% 2284
2017
Q2 		$137K Buy
6,870
+2,011
+41% +$38.9K ﹤0.01% 2448
2017
Q1 		$95K Buy
4,859
+93
+2% +$1.79K ﹤0.01% 2574
2016
Q4 		$88K Buy
4,766
+1,149
+32% +$22K ﹤0.01% 2645
2016
Q3 		$50K Hold
3,617
– – ﹤0.01% 2520
2016
Q2 		$29K Buy
+3,617
New +$40.1K ﹤0.01% 2754

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's RGNX Position: Q1 2026 in Review

Legal & General Group held its Regenxbio (RGNX) position steady in Q1 2026 at 4,022 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Legal & General Group first reported a position in RGNX in Q2 2016 and has held it in 40 quarters since. The position peaked at $5.28M in Q3 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Legal & General Group held 4,022 shares of Regenxbio worth $33.7K as of Q1 2026.
  • Legal & General Group left its Regenxbio share count unchanged in Q1 2026.
  • Regenxbio made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2786 holding.
  • Legal & General Group first reported a position in Regenxbio in Q2 2016 and has held it in 40 quarters since.
  • Legal & General Group's Regenxbio position peaked at $5.28M in Q3 2018.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.